We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume | Trades |
---|---|---|---|---|---|---|
1ADNB | AdAlta Limited | 0.00 | 0.00 | 0.00% | 0.00 | 0 |
1ADO | AdAlta Limited | 0.002 | 0.00 | 0.00% | 0.00 | 0 |
1ADOA | AdAlta Limited | 0.002 | 0.00 | 0.00% | 0.00 | 0 |
1AE | Aurora Energy Metals Ltd | 0.089 | 0.00 | 0.00% | 0.00 | 0 |
1ADNA | AdAlta Limited | 0.00 | 0.00 | 0.00% | 0.00 | 0 |
1ADN | AdAlta Limited | 0.00 | 0.00 | 0.00% | 0.00 | 0 |
14D | 1414 Degrees Limited | 0.071 | 0.00 | 0.00% | 0.00 | 0 |
14DN | 1414 Degrees Limited | 0.00 | 0.00 | 0.00% | 0.00 | 0 |
14DO | 1414 Degrees Limited | 0.008 | 0.00 | 0.00% | 0.00 | 0 |
1AD | AdAlta Limited | 0.027 | 0.00 | 0.00% | 0.00 | 0 |
13S | 13 Seeds Limited | 0.00 | 0.00 | 0.00% | 0.00 | 0 |
The U.S. Orphan Drug Act is intended to assist and encourage companies to develop safe and effective therapies for the treatment of rare diseases and disorders, defined as one that affects fewer than 200,000 people in the U.S. In addition to providing a seven-year term of market exclusivity upon final FDA approval, orphan drug designation also positions Soligenix to be able to leverage a wide range of financial and regulatory benefits, including government grants for conducting clinical trials, waiver of expensive FDA user fees for the potential submission of a Biologics License Application (BLA), and certain tax credits.
HONG KONG, April 17, 2024 /PRNewswire/ -- ICZOOM Group Inc. (Nasdaq: IZM) (the "Company" or "ICZOOM"), announced today that it voluntarily requested a withdrawal of a registration statement on Form F-1 filed with the U.S. Securities and Exchange Commission (File No.333-275708, the "Registration Statement") and accordingly cancelled the proposed public offering pursuant to the Registration Statement .
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that an independent Data Monitoring Committee (DMC) has recommended continuing the pivotal Phase 3 RAISE trial evaluating intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE) following an interim analysis.
Data presentation at highly influential American Society of Breast Surgeons ("ASBrS") Annual Meeting by Dr. Richard Fine wins Scientific Impact Award as voted by breast surgeons President-Elect of the ASBrS, Dr. Michael Berry, presents data and states "cryoablation is ready for prime time" Company seeks indication for treating women with early stage T1 invasive breast cancer with adjuvant hormone therapy Available reimbursement code for facility expense expected to enhance usage upon receiving marketing authorizationMinimally-invasive ProSense® cryoablation offers highly favorable healthcare economics CAESAREA, Israel, April 15, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive ...
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 60,846.76 | -2,994.34 | -4.69% | 1.2T | 7,150,920,844 |
ETH | Ethereum | 2,972.27 | -112.48 | -3.65% | 361.05B | 3,060,912,000 |
USDT | Tether USD | 0.99998 | -0.00002 | 0.00% | 97.83B | 443,173,026 |
BNB | Binance Coin | 533.78 | -4.36 | -0.81% | 84.99B | 467,946,618 |
SOL | Solana | 133.33 | -3.04 | -2.23% | 60.01B | 2,142,431,839 |
STETH | stETH | 2,952.64 | -111.63 | -3.64% | 29.41B | 16,345,765 |
USDC | USD Coin | 1.00 | 0.00 | 0.00% | 28.07B | 1,227,656,387 |
XRP | Ripple | 0.4913 | -0.0054 | -1.09% | 27.07B | 444,042,553 |
DOGE | Dogecoin | 0.14698 | -0.00907 | -5.81% | 21.38B | 639,490,361 |
TONCOIN | Wrapped TON Coin | 6.06 | -0.291393 | -4.59% | 21.16B | 224,211,449 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions